Clearmind Medicine Inc. announced that it has filed a patent application with United States Patent and Trademark Office (USPTO) for the use of 3-methylmethcathinone (with the chemical name 2-(methylamino)-1-(3-methylphenyl)-1-propanon), to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -0.68% | +24.58% | -47.69% |
1st Jan change | Capi. | |
---|---|---|
-47.69% | 4.83M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- CMND Stock
- News Clearmind Medicine Inc.
- Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders